Poxel SA: Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2021
Poxel SA: Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2021 with product launch anticipated in 2021 1 Poxel regained Imeglimin rights from Metavant for US, Europe and other countries not covered by its agreement with Sumitomo Dainippon Pharma and is pursuing next steps to advance its development including partnering activities Poxel continues to prepare for initiation of Phase 2b trial with PXL770 in patients with biopsy-proven NASH and pre-diabetes or type 2 diabetes, expected to commence in H2 2021 PXL065 Phase 2 study ongoing with completion of recruit...
Source: finanznachrichten.de